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Background: To determine the frequency of EVR 
in chronic hepatitis C (CHC) patients treated with 
Interferon and Ribavirin and to compare the effect of 
IL-28B SNP rs12979860 (CC and non CC genotypes) 
on frequency of  EVR. 
Methods: In this  cross-sectional study 100 patients 
with Chronic Hepatitis C (CHC) with genotype 3 
who received Interferon and Ribavirin in the 
standard doses were categorized in two groups 
depending upon the IL-28B SNP rs12979860 CC and 
non CC genotypes. Results of Qualitative PCR for 
HCV RNA after 12 weeks of treatment and EVR 
were entered.  Frequency of EVR in the two groups 
(CC and non CC) was compared. 
Results: Among the 100 patients with Chronic 
Hepatitis C treated with Interferon and Ribavirin, 72 
patients achieved EVR (72%). Out of the 100 
patients, 52 had CC genotype and 48 had non-CC 
genotype (40 with CT and 8 with TT genotype). In 
the CC group 47 out of 52 patients achieved EVR 
(90%) while in the non-CC group 25 out of 48   
patients achieved EVR (52%). The p value in our 
study was 0.00 
Conclusion: The frequency of EVR is 72% in 
Chronic Hepatitis C patients infected with genotype 
3   treated with Interferon and Ribavirin which is 
comparable with Pegylated Interferon and Ribavirin. 
Patients with IL-28B SNP rs12979860 CC genotype 
have a better chance to achieve EVR (90%) as 
compared to the non-CC genotype (52%).   
Key Words: Chronic hepatitis C (CHC), EVR, 
Interferon, Ribavirin, IL28B polymorphism 
Introduction 
Hepatitis C is a global health problem affecting 3% of 
the total world population.1 About 170 million people 
are infected worldwide.2 The prevalence of Hepatitis C 
in  Pakistan is 4.7% which indicates a great burden of 
the disease.3 Hepatitis C is the leading cause of chronic 
hepatitis, cirrhosis and hepatocellular carcinoma.2,4-6  
Because of the high cost of treatment with PEG-IFN, 
Interferon is widely used in developing countries for 
treating Hepatitis C virus infection with good 
results.5,6 
The  treatment response varies among people with 
different ethnicity and better response rates have  been 
studied in Asian patients.1,4  Host genetic factors were 
considered to be important determinants for the 
treatment of CHC. 1,4 Recent genetic studies have 
resolved this issue and confirmed that there is a 
significant association between the single nucleotide 
polymorphisms (SNPs) of Interluekin-28B (IL28B) and 
Sustained virological response (SVR) when patients 
are treated with PegIFN/RBV. 1,4,7,8.In Hepatitis C 
patients receiving treatment better outcomes are seen 
with CC genotype then with CT and TT.8,10 
 Current treatment strategies for CHC treatment 
recommend to decide the duration of treatment on the 
basis of host and viral genotypes and viral responses 
during treatment.4 Early virological response (EVR) is 
an important criteria for the decision to continue or 
terminate the treatment because very few patients who 
cannot achieve EVR can achieve sustained virological 
response (SVR).4,9The positive predictive value(PPV) 
of EVR associated with good treatment compliance is 
very high, achieving SVR in 75% of cases.9 
Asians have  C allele of rs12979860 of IL28B in highest 
 frequency as compared to  people with other 
ethnicity.4 The  CC genotype of rs12979860 has strong 
association with SVR in each population.4 This 
genotype of IL28B is also associated with the 
spontaneous clearance of hepatitis C virus and with on 
treatment viral responses.4,7 Gupta et al showed that 
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among the patients who achieved SVR, 61.1% had CC 
genotype and 38.9% had non-CC genotype. 10 A 
genetic testing for the SNP of IL28B rs12979860has 
been suggested before deciding on treatment strategies 
because it significantly affects the treatment outcome.4 
In a study conducted by Masood et al., EVR was 
achieved in 95.9%  and ETR was achieved in 96.6% of 
chronic hepatitis C patients treated with Interferon 
and Ribavirin.5 It has seen that peg interferon has 
better response than standard interferon for treatment 
of Hepatitis C positive patients.5 
A large number of people infected with HCV infection 
are unaware of their infection. Those who have been 
diagnosed, treatment is not available because of the 
high cost of the treatment.11 When given the treatment 
has high success rates even in the low income 
countries.12 33% of the patients with Chronic Hepatitis 
C develop   liver cirrhosis or hepatocellular 
carcinoma.13 
The limitations of treatment include high cost, the 
need for sophisticated laboratory tests and trained 
clinicians, as well as the limited efficacy and high 
toxicity of some of the medicines.14 
Patients and Methods 
This cross sectional study was conducted at  Centre for 
Liver and Digestive Diseases , Holy Family Hospital, 
Rawalpindi between September to February 2014. One 
hundred  patients with Chronic Hepatitis C (CHC) 
with genotype 3 who received Interferon and 
Ribavirin in the standard doses (Interferon 3 million 
international units subcutaneously thrice weekly and 
Ribavirin800 mg daily in divided doses) for 3 months 
were  categorized in two groups depending upon the 
IL-28B SNP rs12979860 CC and non CC genotypes.    
Patients with Hb > 10g/dl,platelets > 100,000/mm3and 
TLC > 3000/mm3 were included. Patients co-infected 
with Hepatitis B virus and who had ultrasonographic 
evidence of cirrhosis and portal hypertension were not 
included. Patients who developed complications 
during the treatment e.g. thrombocytopenia (Platelet 
count < 80,000/mm3), anemia (Hemoglobin < 8 g/dl) 
and neutropenia (ANC < 1000/mm3) were not 
included because treatment had to be withheld for 
variable period in those patients. Results of Qualitative 
PCR for HCV RNA after 12 weeks of treatment and 
early virological response (EVR) were entered. 
Frequency of EVR in the two groups (CC and non CC) 
was compared. 
Analysis of IL 28B SNP rs12979860 was performed by 
PCR-RFLP protocol in whole blood samples taken 
from Hepatitis C patients included in the study. To 
compare frequency of EVR in CC and non-CC 
genotype, Chi Square Test was applied (p-value <0.05 
was taken statistically significant). Post stratification 
Chi Square test was applied keeping p-value <0.05 as 
statistically significant. 
Results 
 Amongst 100 patients, 46% were males while 54% 
were females . Mean age was 34.03 years (±8.91 years) 
and range was from  18 years to 55 year (Table 1). Fifty 
two  had CC genotype and 48 had non-CC genotype 
(40 with CT and 8 with TT genotype).Females were 
slightly more than males in each group. The 
percentages of males in CC group was 47.9% 
compared to 52.1% females and in non CC genotype 
group, males were 44.2% comparable to 55.8% 
females. Twenty one(43.8%) were up to 30 years of age 
in Non CC group comparable to 27 (56.3%) patients 
with ages more than 30 years. Amongst 52 patients 
with CC genotype, 19 (36.5%) were up to 30 years of 
age compared to 33 (63.5%) patients of ages more than 
30 years (Table 2). The attainment of Early Virological 
Response  (EVR) was observed in 72% of the 100 study 
participants. Among females 38 (70.4%) attained EVR 
and among males 34 (73.9%) achieved EVR (Table 2)   
Majority of the patients 47 (90.4%) with CC genotype 
attained EVR, In the non CC genotype group of 
patients, 25 (52.1%) patients attained EVR. This 
association was observed to be highly statistically 
significant based on Pearson’s chi square test (d.f. 1, χ 
statistic 18.16) with a p- value of 0.00 (Table 2). Even 
though no statistically significant association was 
observed between gender and attainment of EVR (d.f. 
1, χ statistic 1.60, p- value 0.20)  as well as age group 
and attainment of EVR  (d.f. 1, χ statistic 0.15, p- value 
0.69) . 
Table 1: Age groups of the study participants 
according to the gender 
Age (years) Gender Total 
Male  (No (%) Female No (%) 
Upto 30  18(45.0%) 22(55.0%) 40(100%) 
Above 30  28(46.7%) 32(53.3%) 60(100%) 
Total 46% 54% 100% 
Table 2: Post stratification Chi-Square test 
Categories 
based on 
gender or age 







Males Non CC 10(43.4%) 13(56.52%) p-value 
0.007 CC 2(8.69%) 21(91.30%) 
Females Non CC 13(52%) 12(48%) p-value 
0.001 CC 3(10.34%) 26(89.65%) 
Age up to 30 
years 
Non  CC 13(61.90%) 8(38.1%) p-value 
0.000 CC 1(5.26%) 18(94.73%) 
Age above 30 
years 
Non CC 10(37%) 17(63%) p-value 
0.02 CC 4(12.12%) 29(87.87%) 
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Discussion 
Present study results are consistent with the 
international values which describes SVR of 70-80% in 
genotype 3 infected patients treated with PEG IFN and 
Ribavirin. The results are different from a Pakistani 
study conducted which showed an EVR rate of 95.9% 
in chronic hepatitis C patients. 5 Another Pakistani 
study showed an SVR rate of 75-81% in genotype 2 
and 3 infected patients . 6  This study also shows that 
Interferon and Ribavirin combination therapy is still 
an acceptable choice to treat chronic Hepatitis C 
patients with genotype 2 and 3 in our region.  Another 
study by Garcia et al  who analyzed 1014 patients 
showed an EVR rate of 87% in total patients and 96% 
in genotype 2 and 3 infected patients but that study 
was conducted with PEG IFN and RBV. 9 
Our study observed a significant role of IL 28B 
polymorphism on EVR in chronic hepatitis C patients 
infected with Genotype 3 treated. Thomas et al. 
reported the rs12979860 C allele frequency in 
worldwide population, in that C allele frequency was 
23% to 55% in African populations, 52% to 80% in 
European population, 75% to 98% in Southwest 
Asians, and 90% to 100% in East Asian populations. 15  
Our study showed that 52% of the Pakistani 
population have fovourable genotype of IL 28B (CC 
genotype) and thus can achieve good response after 
Interferon and Ribavirin therapy that is a response rate 
of 90%. An Indian study by Gupta et al  showed CC 
genotype in 61% of Indian population with RVR rate 
of 72% in the total population studied. 10 All of these 
patients were infected with genotype 3. 
 Interferon is still used in low-income countries like 
Pakistan to treat chronic hepatitis C with fairly good 
results. Masood et al. showed that EVR was achieved 
in 95.9% and ETR was achieved in 96.6% of chronic 
hepatitis C patients treated with Interferon and 
Ribavirin. 5 It is important as these patients who will 
respond will have reduced risk of developing liver 
cirrhosis and hepatocellular carcinoma which are 
among the leading cause of death in our set up. Our 
study has shown a response rate of 72% in all the 
patients and a very high response rate of 90% in 
patients with the CC Genotype. Since the predictive 
ability of IL28B genotype is strong enough. Therefore, 
it is reasonable to recommend a pre-treatment 
genotyping for SVR prediction. 
Conclusion 
1.The frequency of EVR is 72% in Chronic Hepatitis C 
patients infected with genotype 3 treated with 
Interferon and Ribavirin which is the same as 
described in literature with Pegylated Interferon and 
Ribavirin.  
2. Host genetic factors like IL 28B polymorphism guide 
individualized treatment strategies and aid in 
determining the best treatment plan for each patient 
3. Patients with IL-28B SNP rs12979860 CC genotype 
have  a much better chance to achieve EVR (90%) as 
compared to the non-CC genotype (52%) . 
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